Availability of New Medicines in the US and Germany From 2004 to 2018

Katharina Blankart, PhD; Huseyin Naci, PhD; Amitabh Chandra, PhD

Abstract

IMPORTANCE Germany’s unique approach to coverage determination and pricing has ensured that effective medicines remain on the market, often at prices reduced through negotiation. However, less is known about trade-offs of this approach with regard to initial availability of medicines.

OBJECTIVE To examine differences in the timing and scope of new medicines available in Germany and the US.

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study analyzed initial availability of new medicines approved by regulatory agencies in Germany and the US between January 1, 2004, and December 31, 2018, and followed up through December 31, 2019. Data analysis was conducted from January 1, 2020, to July 1, 2022. A total of 599 novel approvals were reviewed. Generic, biosimilar, vaccine, and combination medicines were excluded.

EXPOSURES US Food and Drug Administration approvals were reviewed for therapies categorized as new molecular entities or new active ingredients. German approvals were reviewed from secondary administrative data of authorized medicines that determine availability in Germany, including data presented by the European Medicines Agency.

MAIN OUTCOMES AND MEASURES Approvals were analyzed to determine the percentage of medicines approved and available in the US, Germany, or both countries and compare the times to reach the market.

RESULTS Analysis of 599 new medicines demonstrated that fewer were available in Germany compared with the US (80% vs 92% of all potential therapies) and that the median difference in time to market was 4 months (95% CI, −44.40 to 44.76 months). Forty-nine medicines were approved in Germany but not in the US, 75% of which were rejected by the US Food and Drug Administration, were withdrawn, or had US equivalent agents.

CONCLUSIONS AND RELEVANCE In this cohort study, fewer new medicines were available in Germany compared with the US between 2004 and 2018. In addition, drugs entered the German market later than in the US.

Introduction

United States policy makers are interested in understanding how other countries approach the challenge of high drug prices. One country that is often highlighted for its unique approach is Germany, which allows manufacturers to set unconstrained prices for medicines at launch but requires that all medicines undergo a systematic assessment of their effectiveness, permitting insurers to renegotiate prices after this assessment. This policy has guaranteed that almost 98% of...
Effective medicines for specific indications are kept on the market and increased the likelihood 10-fold that medicines not deemed beneficial were withdrawn from the market.\textsuperscript{2-4} Moreover, for cancer drugs, price negotiations have resulted in prices being reduced by 24.5\% 1 year after launch.\textsuperscript{5}

Less known, however, is whether the number of medicines available in Germany is meaningfully smaller than what is available in the US. Earlier studies found that new drugs often enter the US market first.\textsuperscript{6,7} The US Food and Drug Administration (FDA) may also approve more medicines in part by relying on surrogate end points, but there is also evidence that the European Medicines Agency (EMA) uses similar end points.\textsuperscript{8} The recent decision to approve a controversial medicine for Alzheimer disease in the US but not in Europe, supports these views.\textsuperscript{9,10} Approvals by the EMA in combination with German requirements for market entry may be more restrictive than US approvals for some medicines but more permissive for others.\textsuperscript{11}

We performed a retrospective cohort study of novel drugs that were available in both the US and Germany, medicines that were available in Germany but not in the US, and medicines that were available in the US but not in Germany. We evaluated the time it took medicines to reach the German market relative to the US market.

In the US, the FDA approves medicines, and commercial payers, which cover one-half of the US population, make their own coverage decisions. However, the process behind commercial insurers’ coverage determinations is opaque and variable across insurers; these determinations are not based on a transparent cost-effectiveness analysis of the type conducted by the Institute for Clinical Effectiveness Research. The 2 largest public payers in the US, Medicare and Medicaid, insure the other half of US citizens and are de facto required to cover most approved therapies (the Veterans Administration uses a formulary but is relatively small; it covers 9 million US citizens, 2.5\% of the population) with some management tools in Medicaid.

In Germany, medicine availability reflects a 3-step process. First, for most new medicines, the EMA makes an approval decision for all European Union member states (this is the mandatory process for treatments for HIV and AIDS, oncology, diabetes, neurodegenerative disorders, autoimmune diseases, and viral diseases).\textsuperscript{12} After this approval, coverage decisions are triggered if manufacturers decide to enter the German market. Manufacturers can apply directly to the German authorities for approving medicines outside of the mandatory classes. Market entry triggers decision-making by the Federal Joint Committee about the drug’s health benefit, which is a nonstate self-governance body that includes payer, health care professional, and patient representatives (created by Arzneimittelmarkt-Neuordnungsgesetz [AMNOG] in 2011).\textsuperscript{5}

Next, the Institute for Quality and Efficiency in Health Care (IQWiG), usually commissioned by the Federal Joint Committee, compares new therapies with standard of care—not placebo—for a given indication and makes a determination of coverage. The institute takes a holistic view of the evidence, including studies not judged by the FDA to be pivotal. As a result, the IQWiG can consider a variety of outcomes, including morbidity, mortality, quality of life, and patient experience, before making a decision. The IQWiG is funded through contributions from all German health insurance funds. Analysis conducted by the IQWiG does not apply to medicines for rare diseases with expected revenues below €50 million per year (US $57 million), which account for almost one-half of all approvals and often have high prices.

Relying on and augmenting the IQWiG analysis, the Federal Joint Committee determines whether the benefit from a medicine is commensurate with the current treatment standard. Depending on the Federal Joint Committee determination, the manufacturer can negotiate a price with insurers, price to match an equivalent medicine, or withdraw the medicine from the market. Before the introduction of AMNOG, health technology assessments were not required regularly to determine negotiated prices and were used in select reference pricing exercises; the pre-AMNOG environment resembled the US situation today.
Methods

Design
This was a retrospective cohort study of all 599 medicines approved in the US and Germany between January 1, 2004, and December 31, 2018, followed up until December 31, 2019. The initial year of analysis is 2004 because it is the year the EMA introduced the mandatory centralized authorization procedure for all new active ingredients approved in European Union Member States. Our focus was on the initial marketing authorization and related activities at the national level. We therefore did not consider subsequent activities that determine prescribing decisions by physicians and use by patients. We also did not consider any withdrawals after initial market entry. Data analysis was conducted from January 1, 2020, to July 1, 2022. This study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Data Sources
To identify novel drug therapies, we used publicly available information from the FDA, the EMA, and data on market launches in Germany based on administrative data. For the US, we considered all medicines approved by the FDA, relying on documents provided through the Orange Book. We included 458 approvals designated as original submissions that were ever approved by the FDA and were categorized as a new molecular entity (type 1) or new active ingredient (type 2) to reflect the somewhat broader definition of a new active substance by European standards. For Germany, we extracted data on 462 novel drug therapies approved using an annual report of the German pharmaceutical market (Arzneiverordnungs-Report) that relies on administrative data provided by ABDATA-Pharma-Daten-Service. Approval is the first time a medicine was available for prescription in the German market, which may deviate from the date of market approval by the EMA or the German national marketing authorization agency because drug presentations need to be registered for marketing. For both the US and Germany, we also checked whether medicines have been available before the starting point of our observation based on the same data sources.

In addition, we collected data from the EMA based on public assessment reports. Within the European Union, medicines may be launched centrally by the EMA, which is the pathway for most new medicines, or by application to national regulators. To validate approval status and additional information, especially for drugs that were not launched in both the US and Germany, we accessed drugbank.com and Gelbe Liste for Germany.

Identifying New Drug Approvals in the US and Germany
We identified 599 unique novel therapies that were launched in the US or German market. We mapped drugs by brand and active ingredient based on the international nonproprietary name. We verified whether the same active pharmaceutical ingredient is marketed under different brand names. We did not consider medicines that were subject to compassionate use or considered as investigational or experimental. We excluded vaccine, generic, and biosimilar agents because these are considered in separate approval processes by the FDA and outside the scope of the German AMNOG process.

Identifying Availability of Medicines by Country
For each medicine, we captured the first date of market availability by month and year. As outcomes based on approval status, we checked whether the 599 medicines were ever available in the US, Germany, or both. For medicines that were approved in 1 of the 2 countries, we identified whether these agents were approved at an earlier time (ie, before 2004) or were never approved.
Determining Availability of Medicines by Approval Status

Approvals were analyzed to determine the percentage of all new medicines available in the US, Germany, or both. We first calculated the percentage of medicines approved in the US and Germany as the percentage of all medicines approved.

For the subset of medicines that we identified to be approved in either the US or Germany, we calculated the difference in approval times in months, with the US approvals as the reference country. We computed the median (95% CI) time difference between approvals. Because the exact month of approval was missing in the German data for 2 medicines, we imputed the mean month (April).

For the subset of medicines that were approved in Germany but not the US, we classified these into 5 categories that are suggestive about potential reasons of nonapproval and 1 residual category. We classified orphan drug designation of medicines using information provided by the EMA for Germany and by the FDA based on the Orphan Drug Designations and Approvals database for the US. We classified small-molecule or biologic drug status based on the type of application process (new drug application compared with biologic application) and data from drugbank.com for medicines approved by the FDA. According to the labeling information, we noted whether medicines were indicated to treat cancer. We also noted whether they were subject to an early assessment of health benefit according to AMNOG in Germany after 2011 by their initial approval date. We classified whether the medicine previously received marketing authorization by the EMA or was suspended. Based on the FDA Orange Book, we determined the priority vs standard review designation.

Statistical Analysis

The 95% significance threshold was determined using unpaired, 2-sided tests. All data were maintained and processed in SAS, version 9.4 (SAS Institute Inc) and analyzed in Microsoft Excel (Microsoft Corp) and SAS.

Results

Table 1 describes our sample of medicines. In total, 599 medicines were approved in either Germany or the US between 2004 and 2018, representing the maximum number of new medicines theoretically available for prescription in these countries.

Of these potential medicines, 12% (n = 73) had already been approved in the US before 2004 (Germany approved these after 2004), and 80% (n = 477) gained approval in the US between 2004 and 2018. Therefore, 91.8% of potential medicines (477 + 73 of 599 medicines) were available in the US. In Germany, 36 (6%) of the 599 possible medicines had been approved before 2004, and 440 (74%) subsequently received approval. Therefore, 79.5% of potential medicines were available in Germany. When we compared time to availability in the US and Germany for the medicines that were approved in both countries, it took 4 months longer for the median therapy (95% CI, −44.40 to 44.76 months) to enter the German market, including the EMA review times. Forty-nine medicines were approved in Germany but not in the US, 75% of which were rejected by the US Food and Drug Administration, were withdrawn, or had US equivalent agents.

Table 1. Medicine Approvals in the United States and Germany, 2004-2018

| Medicine approved in Germany | Medicine approved in the US, frequency (%) | Approved in US before 2004 | Never approved in US | Approved in US in 2004-2018 | Total |
|-----------------------------|------------------------------------------|---------------------------|---------------------|----------------------------|-------|
| Approved in Germany before 2004 | 0 | 0 | 36 (6.01) | 36 (6.01) |
| Never approved in Germany | 0 | 0 | 123 (20.53) | 123 (20.53) |
| Approved in Germany 2004-2018 | 73 (12.19) | 49 (8.18) | 477 (79.63) | 599 (100) |
To understand whether the differences in medicine availability were clinically meaningful, we examined the medicines that were available in either Germany or the US but not in both countries (Table 2). Medicines available only in Germany are noted in Table 3.

Many of the 123 medicines that were available in the US but not in Germany received FDA approval in the most recent year of our study period and therefore could still be approved in the European Union or in Germany (eTable in the Supplement). Ninety-four medicines were not approved by the EMA during the study period, 18 were approved by the FDA in 2018 and could still be approved, and 7 were refused or withdrawn by the EMA. Four medicines with approval, of which 2 had no substitutes, were subsequently approved outside the follow-up period.

Discussion

In this study, we compared the availability of new medicines in the US and Germany. The German system—which relies on the EMA for most approvals—including fewer medicines available during the study period and had access to medicines slightly more slowly, likely due to duration of EMA review. Eighty percent of all potential medicines were available in Germany and 92% were available in the US. This analysis highlights 2 differences between the US and Germany—earlier approvals and more approvals in the US. We found that several medicines that were not ultimately approved by the FDA were available in Germany, and some were subsequently withdrawn by the European Union. Medicines with therapeutic substitutes were available on both markets. More research is needed to determine whether medicines that are available in the US but not in Germany offer added therapeutic benefits over existing alternatives.

The US offers access to a greater number of new medicines, with the approval process marginally faster by 4 months. The process does not seem to compromise safety for speed relative to the European Union and Germany—during our study period, the FDA did not approve several medicines that the European Union subsequently rejected. However, for Medicare and Medicaid, the de facto link between approval and coverage reduces the ability of commercial insurers to refuse

| Approval variable                              | Frequency (%)                                |
|-----------------------------------------------|----------------------------------------------|
|                                               | Not approved in US but approved in Germany (n = 50) | Not approved in Germany but approved in US (n = 123) |
| Orphan drug designation*                      |                                              |
| No                                            | 41 (82.00)                                   | 66 (53.66)                                      |
| Yes                                           | 9 (18.00)                                    | 57 (46.34)                                      |
| Type                                          |                                              |
| Biologic                                      | 8 (16.33)                                    | 24 (19.52)                                      |
| Small molecule                                | 40 (81.64)                                   | 99 (80.48)                                      |
| Stem cell therapy                             | 1 (2.04)                                     | 0                                             |
| Cancer treatment                              |                                              |
| No cancer                                     | 41 (83.67)                                   | 101 (82.11)                                     |
| Cancer                                        | 8 (16.33)                                    | 22 (17.89)                                      |
| Launched before or after AMNOG was implemented|                                              |
| Before                                        | 24 (48.98)                                   | 25 (20.33)                                      |
| After                                         | 25 (51.02)                                   | 98 (79.67)                                      |
| EMA authorization status                      |                                              |
| Not approved                                  | 21 (42.96)                                   | 93 (75.61)                                      |
| Approved\*                                    | 21 (42.86)                                   | 23 (18.70)                                      |
| Withdrawn, refused, suspended                  | 7 (14.29)                                    | 7 (5.69)                                        |

Abbreviations: AMNOG, German Pharmaceutical Market Restructuring Act (Arzneimittelmarktnordnungsgesetz); EMA, European Medicines Agency; FDA, Food and Drug Administration; NA, not applicable.

* The EMA designation for German approvals or FDA designation for US approvals.

\* No approvals with accelerated approval pathways.
Table 3. Medicines Approved in Germany But Not in the US, 2004-2018

| Medicine                                      | Trade name | Indication                                             | Comment                                                |
|-----------------------------------------------|------------|--------------------------------------------------------|-------------|
| Available in Germany without US equivalent at present (n = 6) |            |                                                        |             |
| Carbetocin                                    | Pabal      | Prevention of uterus atony after cesarean delivery     | None        |
| Conchal epithelial cells                      | Holoclair  | Limbal stem cell insufficiency in the eye              | None        |
| Levosimenden                                  | Simdax     | Severe chronic heart failure                           | No novel therapy according to AMNOG                  |
| Nabximols                                     | Sativex    | Spasticity in multiple sclerosis                       | In FDA trials at time of writing                      |
| Velmanase alfa                                | Lamzede    | Alpha-mannosidosis                                      | In FDA trials at time of writing                      |
| Vinfunine                                     | Javor      | Urothelial cancer                                       | None        |
| Available in Germany but rejected by the FDA (n = 12) |            |                                                        |             |
| Alipogene tiparvovec                          | Glybera    | Familial lipoprotein lipase deficiency                  | Weak data and benefit is unlikely to be sustained     |
| Ataluren                                      | Translarna | Duchenne muscular dystrophy                            | Missed primary and secondary end points in multiple studies |
| Corifollitropin                               | Elonva     | Controlled ovarian stimulation                          | Received complete response letter from FDA in 2014    |
| Dapoxetine                                    | Priligy    | Premature ejaculation                                    | Rejected by FDA                                      |
| Idebenone                                     | Raxone     | Leber hereditary optic neuropathy                       | Failed phase 3 trial                                  |
| Lumiracoxib                                   | Prexige    | Osteoarthritic pain                                     | Rejected by FDA, no significant difference vs existing options |
| Mifamurtide                                   | Mepact     | Malignant osteosarcoma                                  | Rejected by FDA                                      |
| Padeliporfin                                  | Tookad     | Low-risk prostate carcinoma                             | Adcom rejected, stating that another drug is more effective without the side effects |
| Pixantrone                                    | Pixuvri    | Non-Hodgkin lymphoma                                    | Rejected by FDA, failed 2 RCTs                        |
| Tivozanib                                     | Fotivda    | Renal cell carcinoma                                    | FDA has rejected multiple times already for weak data |
| Vernakantl                                    | Brinavess  | Antiarrhythmia                                          | Rejected 11-2 by FDA for poor risk-benefit profile   |
| Ximelagatran                                  | Exanta     | Thromboembolism prophylaxis                             | Rejected by FDA for weak efficacy and safety, several anticoagulant alternatives available |
| Available in Germany and subsequently withdrawn (n = 9) |            |                                                        |             |
| Allogenic genetically modified t cells         | Zalmoxis   | Adjuvant therapy for haplo-identical hematopoietic stem cell transplantation | EMA conditional authorization withdrawn in 2019 |
| Catumaxomab                                   | Removab    | Malignant ascites                                       | Voluntarily withdrawn from the market                 |
| Efalizumab                                    | Raptiva    | Psoriasis vulgaris                                      | None        |
| Eptotermin alfa                               | Osigraft   | Tibia fracture with pseudarthrosis                      | None        |
| Gaxilose                                      | LacTest    | Lactose intolerance                                     | Opted out of Germany after AMNOG assessment, never obtained EMA approval |
| Laropiprant with nicotinic acid               | Tredaptive | Dyslipidemia                                            | Shown to have no benefit, previously withdrawn from the EMA by Merck |
| Melagatran                                    | Melagatran (AstraZeneca) | Thromboembolism prophylaxis   | Withdrawn across the board for liver toxic effects |
| Rimobinant                                    | Acomplia   | Obesity                                                 | Withdrawn in 2009                                    |
| Sitaxentan                                    | Thelin     | Pulmonary arterial hypertension                          | Removed from market in 2010; rejected by FDA         |
| Available in Germany and with US equivalents (n = 16) |            |                                                        |             |
| Agomelatin                                    | Valdoxan   | Major depression                                        | No major difference vs bupropion or mirtazapine      |
| Bilastine                                     | Bilosen    | Allergic rhinoconjunctivitis, urticaria                 | Many options in US (some OTC, some prescription, most generic) |
| Ceftobiprol medocaril                         | Zevtera    | Nosocomial pneumonia                                    | Several generic options (including of the same class (cephalosporin)) |
| Cholic acid                                   | Orphaco    | Congenital disorder of primary bile acid synthesis      | Cholbam from Retrophin as their alternative           |
| Delamanid                                     | Deltiba    | Multidrug-resistant tuberculosis                        | Pretomanid is FDA approved                           |
| Desferosederine                               | Tovedeso   | Incontinence                                            | No different than fosferosederine, which is FDA approved |
| Lipigelagratim                                 | Lonquex    | Neutropenia                                             | Pegfilagratim is approved                            |
| Nidfluxacin                                   | Nadixa     | Acne vulgaris                                           | Other options available                              |
| Nomegestrol acetate                           | Zoely      | Oral contraception                                      | Other options available (most generic)               |
| Nomegestrol acetate with estradiol            | Naemis     | Hormone replacement therapy in postmenopausal women     | Other options available                              |
| Racecadeltril                                 | Tiornfan   | Diarrhea in children                                    | Other opioid options available                       |
| Rupatadine                                    | Rupafin    | Allergic rhinitis                                       | Many options in US (some OTC, some prescription, most generic) |
| Tegafur, gimeracil, oteracil                  | Teysuno    | Advanced gastric cancer                                 | None        |
| Tianepine                                     | Tianeurax  | Depression                                              | None        |
| Vidagliptin                                   | Galvus     | Type 2 diabetes                                          | Other options available                              |
| Zofenopril                                    | Biflri, Zofenil | Hypertension, acute myocardial infarction            | None        |

(continued)
coverage, thereby increasing prices. As it stands, the US approval system can lead to high drug prices and an increased likelihood that these medicines are prescribed without strong evidence of efficacy.5 Perhaps most importantly, 10% of US patients remain uninsured, and many insured patients still face significant administrative barriers and cost-sharing to access therapies, such as prior authorizations and step therapy protocols. Access in the US, therefore, is more complicated than regulatory approval. Once a medicine is available in Germany, access to prescription medicines is uniform and cost-sharing is modest—between €5 and €10 (US $5.08-$10.17, as of August 8, 2022)—and independent of patent protection status.

Limitations
This study has limitations. The sample was limited to all medicines approved between 2004 and 2018 and followed up through 2019 such that our findings may not be generalized to medicines in other time periods or to agents that we did not study. In addition, we did not capture withdrawals from the European Union market that are not attributable to decisions made by German authorities.

Conclusions
Our retrospective cohort study of medicines approved in the US and Germany reveals a variety of trade-offs that health systems may wish to consider. These trade-offs may be justifiable but will require more explicit exploration of forgone medicines in Germany, including time differences in market availability owing to reliance on European regulatory frameworks, and higher prices and cost-sharing in the US. Expanding this analysis to other countries, including Canada, the UK, and Japan, to understand the quality of regulatory science in each country would be a fruitful area for future research.

ARTICLE INFORMATION
Accepted for Publication: July 13, 2022.
Published: August 30, 2022. doi:10.1001/jamanetworkopen.2022.29231
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Blankart K et al. JAMA Network Open.
Corresponding Author: Katharina Blankart, PhD, Faculty of Economics and Business Administration, University of Duisburg-Essen, Germany (katharina.blankart@uni-due.de).
Author Affiliations: Faculty of Economics and Business Administration, University of Duisburg-Essen, Essen, Germany (Blankart); London School of Economics, London, United Kingdom (Naci); Harvard Kennedy School, Harvard University, Cambridge, Massachusetts (Chandra).
Author Contributions: Dr Blankart had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Table 3. Medicines Approved in Germany But Not in the US, 2004-2018 (continued)

| Medicine | Trade name | Indication | Comment |
|----------|------------|------------|---------|
| Ferric maltol | Accrufer, Feraccru | Iron deficiency | None |
| Etoricoxib | Arcoxia | Rheumatoid arthritis | Additional safety and efficacy data required |
| Landiolol | Rapibloc | Short-term control of tachyarrhythmias | None |
| Nabimunol | Sativex | Multiple sclerosis | None |
| Oxicapone | Ongentys | Parkinson disease | None |
| Rurioctocog alfa pegol | Adynovi | Hemophilia A | None |

Abbreviations: AMNOG, German Pharmaceutical Market Restructuring Act (Arzneimittelmarktneuordnungsgesetz); EMA, European Medicines Agency; FDA, Food and Drug Administration; OTC, over the counter; RCTs, randomized clinical trials.
Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Blankart, Naci.

Drafting of the manuscript: Blankart, Chandra.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Blankart, Chandra.

Administrative, technical, or material support: Blankart, Naci.

Supervision: Naci, Chandra.

Conflict of Interest Disclosures: Dr Blankart reported receiving personal research fees from Innovation Technology & Innovation Foundation, personal consulting fees from the Robert Bosch Foundation, personal speaking fees from WWZ Forum, and personal consulting fees from Cepton outside the submitted work. Dr Naci reported receiving grants from the Commonwealth Fund, The Health Foundation, UK National Institute for Health Research, and UK Research and Innovation and personal fees for consulting from the Pharmaceutical Group of the European Union outside the submitted work; he serves as a paid advisor to The BMJ. Dr Chandra reported serving on the Congressional Budget Offices Panel of Health Advisors, being an advisor to Kyruss, Health Engine and SmithRX; receiving speaking fees from Washington Speakers Bureau and Leigh Speakers Bureau, travel fees from the Davos Alzheimer’s Collaborative, and being an Academic Affiliate of Analysis Group.

Funding/Support: We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.

Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES
1. Lauenroth VD, Stargardt T. Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? Value Health. 2017;20(7):927-935. doi:10.1016/j.jval.2017.04.006
2. Stern AD, Pietrulla F, Herr A, Kesselheim AS, Sarpotdari A. The impact of price regulation on the availability of new drugs in Germany. Health Aff (Millwood). 2019;38(7):1182-1187. doi:10.1377/hlthaff.2018.05142
3. Robinson JC. Lower prices and greater patient access—lessons from Germany’s drug-purchasing structure. N Engl J Med. 2020;382(23):2177-2179. doi:10.1056/NEJMp2000341
4. Robinson JC, Ex P, Panteli D. Drug price moderation in Germany: lessons for US reform efforts. The Commonwealth Fund. January 23, 2020. Accessed January 14, 2022. https://www.commonwealthfund.org/publications/issue-briefs/2020/jan/drug-price-moderation-germany-lessons-us-reform-efforts
5. Kyle M, Williams H. Is American health care uniquely inefficient? evidence from prescription drugs. Am Econ Rev. 2017;107(5):486-490. doi:10.1257/aer.p20171086
6. Kessler DA, Hass AE, Feiden KL, Lumpkin M, Temple R. Approval of new drugs in the United States: comparison with the United Kingdom, Germany, and Japan. JAMA. 1996;276(22):1826-1831. doi:10.1001/jama.1996.03540200050030
7. Downing NS, Zhang AD, Ross JS. Regulatory review of new therapeutic agents—FDA versus EMA, 2011-2015. N Engl J Med. 2017;367(14):1386-1387. doi:10.1056/NEJMt700103
8. Salcher-Konrad M, Naci H, Davis C. Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Q. 2020;98(4):1219-1256. doi:10.1111/1468-0009.12476
9. Crosson FJ, Covinsky K, Redberg RF. Medicare and the shocking US Food and Drug Administration approval of aducanumab: crisis or opportunity? JAMA Intern Med. 2021;181(10):1278-1280. doi:10.1001/jamainternmed.2021.4610
10. Wexler M. EMA committee votes against approving aduhelm in Europe. Alzheimer’s News Today. November 22, 2021. Accessed January 14, 2022. https://alzheimersnewstoday.com/2021/11/22/ema-committee-votes-against-approving-aduhelm-alzheimers-europe
11. Kashoki M, Hanaizi Z, Yordanova S, et al. A comparison of EMA and FDA decisions for new drug marketing applications 2014-2016: concordance, discordance, and why. Clin Pharmacol Ther. 2020;107(1):195-202. doi:10.1002/cpt.1565
12. Van Norman GA. Drugs and devices: comparison of European and US approval processes. JACC Basic Transl Sci. 2016;1(5):399-412. doi:10.1016/j.jacbts.2016.06.003
13. US Food and Drug Administration. Drugs@fda data files. Accessed February 10, 2022. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files
14. Branch SK, Agranat I. "New drug" designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. J Med Chem. 2014;57(21):8729-8765. doi:10.1021/jm402001w

15. Schwabe U, Paffrath D, Ludwig WD, Klauber J, eds. Arzneiverordnungs—Report 2018. Springer; 2018. doi:10.1007/978-3-662-57386-0

16. ABDATA. Diese seite konnte nicht gefunden warden. Accessed February 10, 2022. https://abdata.de/datenangebot/

17. European Medicines Society. Medicines. Accessed February 10, 2022. https://www.ema.europa.eu/en/medicines/download-medicine-data

18. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(database issue):D668-D672. doi:10.1093/nar/gkj067

19. Gelbe Liste. Accessed February 10, 2022. https://www.gelbe-liste.de/

SUPPLEMENT.

eTable. Medicines Approved in the US But Not in Germany